A Phase 1 interventional study of Olaratumab and Doxorubicin in Soft Tissue Sarcoma, sponsored by Eli Lilly and Company. Completed at 14 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-12.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies testing doxorubicin in Sarcoma — 13 open to participants now, 14 under way, 2 of them phase 3. Doxorubicin · Sarcoma.
Among the 65 studies testing doxorubicin in Sarcoma, this one is the 23rd largest by enrollment of the 60 interventional ones that give a count, is one of 6 that started in 2016, is one of 15 in phase 1, and was the 44th registered.
1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.
Browse Sarcoma studies →13 of the 65 studies testing doxorubicin in Sarcoma are open now, in 7 countries. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 65–100
Swiss Cancer Institute · Sites in Switzerland
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 10+
Fudan University · Sites in China
Ages 18–75
By country, each count listing its studies:
Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 38 · Phase 3 12
First in 1990; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is above the median of 41 across 1,254 interventional studies indexed under Sarcoma.
Median enrollment 42 across the 60 interventional studies. Of the 43 that completed or were terminated, 13 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 65 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
17 studies in Sarcoma by Eli Lilly and Company: none open now, 1 under way, none of them phase 3. Of 15 finished, 14 (93%) have results posted.
Among the 17 studies in Sarcoma by Eli Lilly and Company, this one is the 7th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2016, is one of 6 in phase 1, and was the 9th registered.
Eli Lilly and Company’s Sarcoma studies by the year they started, since 2007.
2 of the studies testing doxorubicin in Sarcoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03805022Phase 3Institut BergoniéBenefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas | 2026-12 |
| NCT05711615National Cancer Institute (NCI)Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | 2027-05-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 65 studies testing doxorubicin in Sarcoma, from their registry updates:
Among Eli Lilly and Company’s 17 in Sarcoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate potential biomarkers and method of action, efficacy and safety of olaratumab in participants with soft tissue sarcoma (STS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cycle 1: Olaratumab 20 milligram per kilogram (mg/kg) given intravenously (IV) on Day 1 and Day 8 (21 day cycle). Cycle 2: Olaratumab 20 mg/kg given IV on Day 1 and Day 8 plus doxorubicin 75 mg/m2 given IV on Day 1 (21 day cycle). Cycle 3 through Cycle 7: Olaratumab 15 mg/kg given IV on Day 1 and Day 8 plus doxorubicin 75 mg/m2 given IV on Day 1 (21 day cycles).
Drug: Olaratumab · Drug: Doxorubicin
Olaratumab given IV on Day 1 and Day 8 (21 day cycle) concurrently with radiotherapy. Radiotherapy addendum was not implemented.
Drug: Olaratumab · Radiation: External Beam Radiotherapy
Administered IV
Also known as: LY3012207
Administered IV
Percent Change From Baseline in Enumeration of Circulating Tumor Cells (CTCs) in Whole Blood
Enumeration of CTCs pre- and post- treatment with olaratumab may be a useful biomarker given the predilection for sarcomas to spread hematogenously.
Time frame: Baseline, End of Cycle 1 (21 days)
Percent Change From Baseline in Gene Expression of Platelet-Derived Growth Factor Receptor Alpha (PGDFRα) and PGDFR Beta (β) in Tumor Tissue
Over-activity of PDGF signaling is associated with the development of certain malignant diseases. Olaratumab is an IgG1 antagonist of PDGFRα.
Time frame: Baseline, End of Cycle 1 (21 days)
Percent Change From Baseline in Gene Expression of PDGF A, PDGF B, PDGF C, and PDGF-D Canonical Ligands in Tumor Tissue
PDGF A, PDGF B, PDGF C, and PDGF D are platelet-derived growth factor canonical ligands associated with activation of PDGFR α and β.
Time frame: Baseline, End of Cycle 1 (21 days)
Progression Free Survival (PFS)
Progression-free survival (PFS) is defined as the time from the date of first study dose to the first date of radiologic disease progression or death due to any cause. Progressive disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). The appearance of one or more new lesions is also considered progression.
Time frame: Baseline to Objective Progression or Death from Any Cause (Up to 18 Months)
Objective Response Rate (ORR): Percent of Participants With Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR)
Overall Response Rate (ORR) is defined as the percentage of participants achieving a best overall response of either Complete Response (CR) or Partial Response (PR) as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR is defined as a disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to \<10 mm and normalization of tumor marker results; PR is defined as at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. The best overall response is the best response from the start of the treatment until progressive disease (PD)/recurrence.
Time frame: Baseline to Measured Progressive Disease (Up to 18 Months)
Disease Control Rate (DCR): Percent of Participants Who Exhibit Stable Disease (SD), CR or PR
Disease control rate (DCR) is defined as the percentage of participants achieving a best overall response of CR, PR, or SD as determined by RECIST 1.1. CR is defined as a disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to \<10 mm and normalization of tumor marker results; PR is defined as at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters; SD is defined as neither sufficient shrinking to qualify as PR nor sufficient increase to qualify for PD. Participants who do not have any post-baseline tumor response assessments for any reason are considered non-responders and are included in the denominator when calculating the response rate.
Time frame: Baseline to Measured Progressive Disease (Up to 18 Months)
Percentage of Participants With Resectable Tumors (Resectability Rate)
Resectability rate is obtained when the total number of participants with resectable tumors is divided by the total number of participants. Resectability of a tumor is determined by the surgeon and multi-disciplinary team and dependent on tumor stage and the participants coexisting medical conditions.
Time frame: Cycle 1 through Cycle 7 (Up to 6 Months)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Olaratumab Monotherapy
Summary of Cmax of olaratumab monotherapy on Cycle 1 Day 1 and Day 8
Time frame: Cycle 1 Days 1 and 8: Predose; 5 minutes(m) post-infusion
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Olaratumab
Cmax of olaratumab Cycles 2 and 3 Day 1 and 8 of a 21-day cycle.
Time frame: Cycle 2 Day 1: Predose, 5 minutes(m) post-infusion, 24 hours(h), 96h; Day 8:Predose, 5 m, and 24h, 48h, 96h, and 240h postdose; Cycle 3 Day 1 and Day 8: Predose and 5m post-infusion
Number of Participants With Anti-Olaratumab Antibodies
A participant is counted as positive if they had at least one anti-olaratumab antibody positive result during the study.
Time frame: Predose Cycle 1 Day 1 through Follow-Up (Up to 8 Months)
Participants are considered to have completed the study if they completed one cycle of monotherapy and all 6 cycles of combination therapy.
| Milestone | Olaratumab + Doxorubicin |
|---|---|
| Started | 51 |
| Received at least one dose of study drug | 51 |
| Completed | 11 |
| Not completed | 40 |
| Withdrew: Progressive disease | 23 |
| Withdrew: Surgical resection | 10 |
| Withdrew: Adverse event | 4 |
| Withdrew: Physician decision | 2 |
| Withdrew: Death | 1 |
Enumeration of CTCs pre- and post- treatment with olaratumab may be a useful biomarker given the predilection for sarcomas to spread hematogenously.
| percent change | Olaratumab |
|---|---|
| Traditional CTCs | 846.93 ± 3260.60 |
| All Population CTCs | 820.11 ± 3263.41 |
Over-activity of PDGF signaling is associated with the development of certain malignant diseases. Olaratumab is an IgG1 antagonist of PDGFRα.
| percent change in gene expression | Olaratumab |
|---|---|
| PDGF Receptor α | 6162.86 ± 32383.49 |
| PDGF Receptor β | 1246.25 ± 7024.82 |
PDGF A, PDGF B, PDGF C, and PDGF D are platelet-derived growth factor canonical ligands associated with activation of PDGFR α and β.
| percent change in gene expression | Olaratumab |
|---|---|
| Canonical Ligand PDGF - A | 189.37 ± 672.91 |
| Canonical Ligand PDGF - B | 602.01 ± 2798.92 |
| Canonical Ligand PDGF - C | 1107.45 ± 6053.12 |
| Canonical Ligand PDGF - D | 2630.36 ± 14425.92 |
Progression-free survival (PFS) is defined as the time from the date of first study dose to the first date of radiologic disease progression or death due to any cause. Progressive disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). The appearance of one or more new lesions is also considered progression.
| months | Olaratumab + Doxorubicin |
|---|---|
| Progression Free Survival (PFS) | 2.86 (1.41 to 9.72) |
Overall Response Rate (ORR) is defined as the percentage of participants achieving a best overall response of either Complete Response (CR) or Partial Response (PR) as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR is defined as a disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to \<10 mm and normalization of tumor marker results; PR is defined as at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. The best overall response is the best response from the start of the treatment until progressive disease (PD)/recurrence.
| percentage of participants | Olaratumab + Doxorubicin |
|---|---|
| Objective Response Rate (ORR): Percent of Participants With Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) | 11.8 |
Disease control rate (DCR) is defined as the percentage of participants achieving a best overall response of CR, PR, or SD as determined by RECIST 1.1. CR is defined as a disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to \<10 mm and normalization of tumor marker results; PR is defined as at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters; SD is defined as neither sufficient shrinking to qualify as PR nor sufficient increase to qualify for PD. Participants who do not have any post-baseline tumor response assessments for any reason are considered non-responders and are included in the denominator when calculating the response rate.
| percentage of participants | Olaratumab + Doxorubicin |
|---|---|
| Disease Control Rate (DCR): Percent of Participants Who Exhibit Stable Disease (SD), CR or PR | 52.9 |
Resectability rate is obtained when the total number of participants with resectable tumors is divided by the total number of participants. Resectability of a tumor is determined by the surgeon and multi-disciplinary team and dependent on tumor stage and the participants coexisting medical conditions.
| percentage of participants | Olaratumab + Doxorubicin |
|---|---|
| Percentage of Participants With Resectable Tumors (Resectability Rate) | 35.3 (22.4306 to 49.9318) |
Summary of Cmax of olaratumab monotherapy on Cycle 1 Day 1 and Day 8
| micrograms per milliliter (µg/mL) | Olaratumab |
|---|---|
| Cycle 1 Day 1 | 510 ± 22 |
| Cycle 1 Day 8 | 661 ± 24 |
Cmax of olaratumab Cycles 2 and 3 Day 1 and 8 of a 21-day cycle.
| micrograms per milliliter (µg/mL) | Olaratumab + Doxorubicin |
|---|---|
| Cycle 2 Day 1 | 624 ± 26 |
| Cycle 2 Day 8 | 711 ± 28 |
| Cycle 3 Day 1 | 521 ± 30 |
| Cycle 3 Day 8 | 601 ± 32 |
A participant is counted as positive if they had at least one anti-olaratumab antibody positive result during the study.
| Participants | Olaratumab + Doxorubicin |
|---|---|
| Number of Participants With Anti-Olaratumab Antibodies | 1 |
Collected over Baseline to end of study (Up to 46 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olaratumab + Doxorubicin | 3/51 (5.9%) | 22/51 (43.1%) | 50/51 (98%) |
| Event | Olaratumab + Doxorubicin |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 9/51 |
| SepsisInfections and infestations | 2/51 |
| AnaemiaBlood and lymphatic system disorders | 1/51 |
| Atrial fibrillationCardiac disorders | 1/51 |
| Cardiopulmonary failureCardiac disorders | 1/51 |
| DiarrhoeaGastrointestinal disorders | 1/51 |
| Gastrointestinal obstructionGastrointestinal disorders | 1/51 |
| Intestinal perforationGastrointestinal disorders | 1/51 |
| StomatitisGastrointestinal disorders | 1/51 |
| PyrexiaGeneral disorders | 1/51 |
| Event | Olaratumab + Doxorubicin |
|---|---|
| NauseaGastrointestinal disorders | 27/51 |
| FatigueGeneral disorders | 24/51 |
| StomatitisGastrointestinal disorders | 22/51 |
| ConstipationGastrointestinal disorders | 20/51 |
| Decreased appetiteMetabolism and nutrition disorders | 17/51 |
| AlopeciaSkin and subcutaneous tissue disorders | 16/51 |
| AstheniaGeneral disorders | 13/51 |
| DiarrhoeaGastrointestinal disorders | 12/51 |
| VomitingGastrointestinal disorders | 12/51 |
| AnaemiaBlood and lymphatic system disorders | 11/51 |
All participants who received at least one dose of study drug.
| Age, Categorical(Participants) | Olaratumab + Doxorubicin |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 37 |
| >=65 years | 14 |
| Sex: Female, Male(Participants) | Olaratumab + Doxorubicin |
|---|---|
| Female | 24 |
| Male | 27 |
| Ethnicity (NIH/OMB)(Participants) | Olaratumab + Doxorubicin |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 44 |
| Unknown or Not Reported | 3 |
| Race (NIH/OMB)(Participants) | Olaratumab + Doxorubicin |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 47 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Olaratumab + Doxorubicin |
|---|---|
| United States | 17 |
| Italy | 3 |
| United Kingdom | 4 |
| France | 2 |
| Spain | 25 |
| Circulating Tumor Cells (CTC)(CTC per milliliter) | Olaratumab + Doxorubicin |
|---|---|
| Traditional CTC | 2.183 ± 2.631 |
| All Population CTC | 2.446 ± 2.797 |
| Platelet-Derived Growth Factor Receptor Alpha (PGDFRα ) and PGDFR Beta (β)(relative gene expression units) | Olaratumab + Doxorubicin |
|---|---|
| PGDFRα | 301.68 ± 570.79 |
| PGDFRβ | 812.49 ± 1260.23 |
| PDGF Canonical Ligands -A, -B, -C, -D(relative gene expression units) | Olaratumab + Doxorubicin |
|---|---|
| PGDF-A | 12.90 ± 18.46 |
| PDGF-B | 230.62 ± 1151.87 |
| PDGF-C | 227.68 ± 447.56 |
| PDGF-D | 33.22 ± 69.99 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2016 to primary completion in Jul 2018, 20 months.
Results were first posted in Aug 2019, 1 year 1 month after primary completion.
Of 72 industry-sponsored phase 1 interventional studies under Sarcoma, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 66. This study's 20 months is below that.
Counting every sponsor, half of 161 studies reached it within 56 months; a quarter within 35 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doxorubicin